(Nasdaq: JAGX) Surges Green Behind Breaking News Early Wednesday (Low Float)

Jaguar Health, Inc. (Nasdaq: JAGX) is making buzz behind a solid green move early Wednesday.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored (Nasdaq: JAGX) Surges Green Behind Breaking News Early Wednesday (Low Float) *Get Our Updates Faster—Tap Here To Receive SMS Alerts* April 8th Greetings, Friend! Jaguar Health, Inc. (Nasdaq: JAGX) is making buzz behind a solid green move early Wednesday. Also making buzz? How about JAGX's breaking news today? Take a look: Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs Topline results expected within a month and may complement positive results of a study of crofelemer for treatment of cancer therapy-induced diarrhea (CTD) in dogs receiving neratinib - a targeted tyrosine kinase inhibitor (TKI) SAN FRANCISCO, CA / ACCESS Newswire / April 8, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that the Company has completed the company's ongoing effectiveness study of crofelemer delayed-release tablets for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Crofelemer, under the name Canalevia-CA1, is currently conditionally approved for the sole indication of treating CID in dogs. The approval for Canalevia CA-1 will expire on December 21, 2026. "We're very pleased that enrollment has concluded for this study, which is being undertaken at veterinary oncology clinics around the US. The FDA granted renewal of the conditional approval for Canalevia-CA1 for a fifth and final year, through December 21, 2026, for the treatment of CID in dogs. In order to receive a full veterinary drug approval for the indication of CID beyond Dec. 21, 2026, Jaguar must complete and file a successful effectiveness study," said Dr. Michael Guy, D.V.M., M.S., Ph.D., Jaguar's Vice President of Preclinical and Nonclinical Studies. In the second quarter of 2026 Jaguar plans to submit and file the results of the company's effectiveness study and the positive results of a study of crofelemer delayed-release tablets for treatment of CTD in dogs receiving neratinib - a targeted tyrosine kinase inhibitor (TKI) chemotherapy agent. "The 28-day study in dogs receiving neratinib was designed to evaluate the scientific rationale for the use of crofelemer tablets in reducing the severity and incidence of diarrhea in cancer patients receiving neratinib, a targeted therapy known to cause significant diarrhea," said Dr. Guy. "The study demonstrated that crofelemer dosing resulted in a 30% reduction in the incidence and severity of diarrhea in participating dogs, which was statistically significant." ... Read the full article here. Remember. JAGX is a low float idea. With fewer than 3Mn shares in its float, the potential for heightened volatility cannot be discounted. Review my initial (Nasdaq: JAGX) report below and consider this profile for your radar. ----- In the fast-changing landscape of medical innovation, one company is addressing critical gaps in global health that have long gone overlooked. By focusing on novel therapies designed for complex gastrointestinal conditions, it’s advancing solutions that promise better quality of life for patients facing limited treatment options. Backed by a team deeply rooted in clinical science and translational research, the company’s progress reflects an uncommon blend of scientific rigor and purpose-driven vision. Its recent developments signal a profile worth exploring for anyone following transformative health technology. And with a low float under 3Mn shares and this week's announcement of revenue growth, this under-the-radar Nasdaq idea tops our watchlist Wednesday:  Jaguar Health, Inc. (Nasdaq: JAGX) Jaguar Health, Inc. ("Jaguar") is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Jaguar Health, Inc., in conjunction with Jaguar family company Napo Pharmaceuticals, Inc. (“Napo”), develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal (“GI”) disease states.  Jaguar family companies Napo and Napo Therapeutics, S.p.A., an Italian corporation Jaguar established in Milan, Italy in 2021, are focused on expanding global crofelemer access and are developing new therapies for orphan and rare GI conditions. How Crofelemer Works Crofelemer is a non-opioid that works differently from other treatments for GI dysfunction: From Tree to Bottle, Crofelemer was discovered through the science of ethnobotany. Mytesi Is a Novel, First-in-Class Antisecretory Agent Mytesi is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy (ART). Mytesi has a novel mechanism of action that modulates chloride secretion in the gastrointestinal tract, reducing excessive chloride and accompanying water flow and relieving watery diarrhea. What is Canalevia-CA1? Canalevia-CA1 normalizes fluid flow to reinstate normal function in the GI tract and is an antidiarrheal, enteric-coated tablet for oral administration. It acts locally and it is not absorbed into the bloodstream, resulting in a well tolerated and non-opioid drug product. It is naturally and sustainably harvested from the sap of a medicinal tropical plant, the Croton lechleri tree. Human Health Product Portfolio Animal Health Product Portfolio Estimated Size of Mytesi Target Markets The Company believes the medical need for Mytesi is significant, compelling, and unmet, and that doctors are looking for a drug product with a mechanism of action that is distinct from the options currently available to resolve diarrhea.  A growing percentage of HIV patients have lived with the virus in their guts for 10+ years, often causing gut enteropathy and chronic or chronic episodic diarrhea. According to data from the U.S. Centers for Disease Control and Prevention, it was estimated that by 2020 more than 70% of Americans with HIV were 50 and older and had lived with HIV for more than 10 years. Find Sources And More: JAGX Website. JAGX Presentation. JAGX Form 10-K. ----- (Nasdaq: JAGX) And Its 5 Key Potential Catalysts On Our Radar #1. JAGX Has A Very Low Float (Volatility Potential Could Be Explosive). With a float of roughly 2.61Mn shares, according to the Yahoo Finance website, the potential for heightened volatility could be significant. #2. Jaguar Health Demonstrates Resilient Revenue Growth And Strategic Commercial Progress. Jaguar Health reported fourth-quarter 2025 revenue of $3.2Mn, reflecting sequential growth and steady commercial execution across its portfolio, including Mytesi, Gelclair, and Canalevia. The quarter-over-quarter increase signals improving operational momentum and stabilization. A diversified mix of prescription, non-prescription, and licensing revenue highlights Jaguar’s expanding market reach. This performance underscores the company’s continued progress in strengthening its commercial foundation while positioning key products for future growth, supporting long-term value creation and reinforcing confidence in its strategic direction and execution capabilities. #3. FDA Support Advances Crofelemer Trial For Rare Pediatric Disease Treatment. FDA support for Jaguar’s crofelemer trial extension in MVID marks a significant regulatory and clinical milestone. The planned single-blind extension phase enables longer treatment evaluation, potentially reducing reliance on parenteral support and improving patient outcomes in this life-threatening pediatric condition. With no approved therapies currently available, crofelemer’s progress highlights Jaguar’s leadership in addressing critical unmet needs. #4. A Key Jaguar Partnership Explores Novel Plant Based Therapy For Weight Management. Jaguar’s joint venture Magdalena Biosciences has initiated a promising preclinical study evaluating coca leaf extract for appetite suppression, targeting post-G-L-P-1 weight management. This innovative, plant-based approach leverages traditional knowledge alongside modern drug development under FDA botanical guidance. The program expands Jaguar’s pipeline into metabolic and CNS indications, including potential applications for ADHD. With growing demand for sustainable weight management solutions, this research positions Jaguar at the forefront of novel therapeutics. #5. The Company Strengthened Their Financial Position Through Debt Reduction And Strategic Restructuring. Jaguar Health significantly strengthened its financial foundation by reducing debt and royalty obligations while extending key maturities, improving flexibility and lowering near-term financial pressure. The restructuring included a $3Mn reduction and elimination of over 48,000 warrants, enhancing capitalization. By pushing debt maturities beyond mid-2026, Jaguar gains valuable runway to advance its crofelemer development programs. This proactive financial strategy aligns with ongoing business development efforts aimed at securing non-dilutive funding. ----- Coverage is officially kicked off on Jaguar Health, Inc. (Nasdaq: JAGX). Updates will be coming your way soon. Talk again shortly. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 04/08/2026 and ending on 04/08/2026 to publicly disseminate information about (JAGX:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named RazorPitch Inc. who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (JAGX:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/jagx-kuqaf/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice